FDA Cites Akorn’s Exhibit Banner At ASHP Clinical Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
Booth promotion for Nembutal fails to disclose any risk information, Office of Prescription Drug Promotion says in the fifth letter issued this year.
You may also be interested in...
FDA's Decline In Promotion Enforcement Highlighted By Celator Booth Letter
FDA's Office of Prescription Drug Promotion issues only its third letter of 2016, although it hopes to cast wide net by targeting high-profile events like ASCO.
FDA Turns Off Otsuka’s Abilify Dimmer Switch Graphic
As lights go out on the franchise, FDA says pharmacology aid misleadingly suggests Abilify offers advantages over other treatments.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.